Podcasts about Pediatric Neurology

Send us a textIn this episode, Dr. Amy Gelfand, a child neurologist specializing in pediatric headaches, discusses the complexities and treatment of migraines in children. Gelfand explains the genetic nature of migraines and their commonality among kids, noting triggers like menstrual cycles and changes in sleep patterns. She elaborates on distinguishing features of migraines and provides insight into preventive and acute treatments, including NSAIDs, triptans, neuromodulation devices, and supplements. The discussion also covers the importance of a regular schedule, the benefits of cognitive behavioral therapy (CBT), and recent advancements in migraine-specific medications. Dr. Gelfand emphasizes the significant progress in migraine treatment and encourages families to consult specialists for personalized care.About Dr Gelfand:Dr. Amy Gelfand is a pediatric neurologist who specializes in diagnosing and treating children with a variety of headache disorders, as well as those with childhood periodic syndromes (such as abdominal migraine), which may be precursors to migraine headache later in life. Her research focuses on the epidemiology of pediatric migraine and childhood periodic syndromes.Gelfand received her medical degree from Harvard Medical School. She completed residencies in pediatrics and child neurology at UCSF.Gelfand has received a teaching award from the UCSF pediatric residency program and writing awards from the medical journal Neurology. She is a member of the American Academy of Neurology, Child Neurology Society and American Headache Society.Your Child is Normal is the trusted podcast for parents, pediatricians, and child health experts who want smart, nuanced conversations about raising healthy, resilient kids. Hosted by Dr. Jessica Hochman — a board-certified practicing pediatrician — the show combines evidence-based medicine, expert interviews, and real-world parenting advice to help listeners navigate everything from sleep struggles to mental health, nutrition, screen time, and more. Follow Dr Jessica Hochman:Instagram: @AskDrJessica and Tiktok @askdrjessicaYouTube channel: Ask Dr Jessica If you are interested in placing an ad on Your Child Is Normal click here or fill out our interest form.-For a plant-based, USDA Organic certified vitamin supplement, check out : Llama Naturals Vitamin and use discount code: DRJESSICA20-To test your child's microbiome and get recommendations, check out: Tiny Health using code: DRJESSICA The information presented in Ask Dr Jessica is for general educational purposes only. She does not diagnose medical conditi...

In this Ask Dr. Tony episode, Dr. Tony Ebel tackles one of the most requested questions: Can chiropractic care help with OCD? He explains how OCD is rooted in a nervous system stuck in 24/7 fight-or-flight mode and breaks down the neuroscience behind it—including the roles of the amygdala, prefrontal cortex, and vagus nerve. Dr. Tony reveals why traditional approaches often miss the mark and how neurologically-focused chiropractic care works from the inside out to calm an overactive nervous system and create a stronger foundation for healing. This episode offers real, drug-free hope to families struggling with OCD and anxiety.-----Links & ResourcesResearch shows kids with OCD and anxiety often have altered prefrontal cortex activity, affecting focus, emotional control, and behavior. (Neuropsychopharmacology, 2021), (Springer, 2023)-----Key Topics & Timestamps05:00 The Smoke Alarm Analogy: Why the Brain Gets Hardwired for Anxiety08:00 Deep Dive into Brain Science: What's Really Happening with OCD13:00  How the Amygdala Hijacks the Higher Brain Centers17:00 Chemistry Follows Neurology: Why Medication Alone Isn't Enough21:00 The Vagus Nerve: The Missing Link in OCD Treatment28:00 Real Patient Story: "As Long as I'm Perfect, I'm Okay"33:00 The Perfect Storm Pathway: From Pregnancy to Present Day Stressors36:00 The INSiGHT Scan Process: Finding & Clearing Subluxations39:00 The One-Plus-One-Equals-11 Effect: Making Other Interventions Work Better40:00 How You'll Know It's Working: Signs of Nervous System Regulation42:00 How to Find a PX Doc & Get Started with Care-- Follow us on Socials: Instagram: @pxdocs Facebook: Dr. Tony Ebel & The PX Docs Network Youtube: The PX Docs For more information, visit PXDocs.com to read informative articles about the power of Neurologically-Focused Chiropractic Care. Find a PX Doc Office near me: PX DOCS DirectoryTo watch Dr. Tony's 30 min Perfect Storm Webinar: Click Here

Pediatric neuropalliative medicine is an emerging area of subspecialty practice that emphasizes the human experience elements of serious neurologic illness. Child neurologists care daily for patients who can benefit from the communication strategies and management practices central to pediatric neuropalliative medicine, whether at the primary or subspecialty level. In this episode, Gordon Smith, MD, FAAN, speaks with Lauren Treat, MD, author of the article "Neuropalliative Medicine in Pediatric Neurology" in the Continuum® December 2025 Neuropalliative Care issue. Dr. Smith is a Continuum® Audio interviewer and a professor and chair of neurology at Kenneth and Dianne Wright Distinguished Chair in Clinical and Translational Research at Virginia Commonwealth University in Richmond, Virginia. Dr. Treat is an associate professor in the divisions of child neurology and palliative medicine at the University of Colorado School of Medicine in Aurora, Colorado. Additional Resources Read the article: Neuropalliative Medicine in Pediatric Neurology Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @gordonsmithMD Full episode transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME, subscribing to the journal, and exclusive access to interviews not featured on the podcast. Dr Smith: This is Gordon Smith. Today I've got the great pleasure of interviewing my good friend Dr Lauren Treat about her article on neuropalliative medicine in pediatric neurology practice. This article appears in the December 2025 Continuum issue on neuropalliative care. Lauren, welcome to the Continuum podcast, and maybe you can introduce yourself to our listeners. Dr Treat: Such a delight to be here, Gordon. Thank you. I am a pediatric neurologist and palliative medicine doctor at the University of Colorado, Children's Hospital Colorado, and I am practicing in both areas. I do general child neurology, and I also run a pediatric neuropalliative medicine clinic. So, I'm happy to be here to talk about it. Dr Smith: And, truth in advertising, I tried very hard to get Dr Treat to move to VC to work with me. And I haven't given up yet. I'm looking forward to the conversation. And Lauren, I wonder- one, I'm really excited about this issue, by the way. This is the second podcast I've done. And I'd like to ask the same question I asked of David Oliver, who's amazing. What a great article and conversation we had. And that question is, can you define palliative care? I think a lot of people think of it as, like, end-of-life care or things like that. And is the definition a little different in the pediatric space than it is in the adult space? Dr Treat: Such a great place to start, Gordon. I absolutely think that there are nuances that are very important in pediatrics. And we especially acknowledge in pediatrics that there is a very longitudinal component of this. And even moreso, I think, then in adult neuropalliative medicine, in pediatrics, we are seeing people=even prenatally or early in their first hours and days of life, and walking with them on a journey that might last days or weeks, but might last years or decades. And so, there is this sense that we are going to come alongside them and be part of the ups and the downs. So yes, neuropalliative medicine is a kind of medicine that is a very natural partner to where neurology is in its current field. We're doing a lot of exciting things with modifying diseases, diagnosing things early, and we have a very high reliance on the things that we can measure in medicine. And not all things can be measured that are worthwhile about one's quality of life. A family very poignantly told me very recently, making sure someone stays alive is different from making sure they have a life. And that's what neuropalliative medicine is about. Dr Smith: Well, great summary, and I definitely want to follow up on several aspects of that, but there's one point I was really curious about as I've been thinking about this, you know, these are really exciting times and neurology in general and in child neurology in particular. And we've got all of these exciting new therapies. And as you know, I'm a neuromuscular person, so it's hard not to think back on SMA and not be super excited. And so, I wonder about the impact of these positive developments on the practice of neuropalliative care in kids. You know, I'm just thinking, you know, you mentioned it's a journey with ups and downs. And I wonder, the complexity of that must be really interesting. And I bet your job looks different now than it did seven or eight years ago. Dr Treat: That's absolutely true. I will self-reference here one of the figures in the paper. Figure 2 in my section is about those trajectories, about how these journeys can have lots of ups and downs and whether this person had a normal health status to begin with or whether they started out life with a lot of challenges. Those ups and downs inherently involve a lot of uncertainty. And that's where palliative medicine shines. Not because we have the answer---everyone would love for us to have the answer---but because we consider ourselves uncertainty specialists in the way that we have to figure out what do we know, what can we ground ourselves in, and how can we continue to move forward even if we don't have all the answers? That is a particular aspect of neurology that is incredibly challenging for families and clinicians, and it can't stand as a barrier to moving forward and trying to figure out what's best for this child, what's best for this family. What do we know to be true about them as people, and how can we integrate that with all of the quantitative measures that we know and love in neurology? Dr Smith: So, I love the comment about prognostication, and this really ties into positive uncertainty or negative undercertainty in terms of therapeutic development. I wonder if you can talk a little bit about your approach to prognostication, particularly in a highly fluid situation. And are there pearls and pitfalls that our listeners should consider when they're discussing prognosis for children, particularly maybe young children who have severe neurological problems? Dr Treat: It's such a pivotal issue, a central issue, to child neurology practice. Again, because we are often meeting people very, very early on in their journey---earlier than we ever have before, sometimes, because of this opportunity to have a diagnosis, you know, prenatally or genetically or whatever else it is---sometimes we are seeing the very early signs of something as compared to previously where we wouldn't have a diagnosis until something was in its more kind of full-blown state. This idea of having a spectrum and giving people the range of possible outcomes is absolutely still what we need to do. However, we need to add on another skill on top of that in helping people anchor into what feels like the most likely situation and what the milestones are going to be in the near future, about how we're going to walk this journey and what we'll be on the lookout for that will help us branch into those different areas of the map down the road. Dr Smith: So, I wonder if we can go back to the framework you mentioned, two answers ago, I think? You and the article, you know, provide four different types of situations kind of based on temporal progression. I wonder if maybe the best way of approaching is to give an example and how that impacts your thoughts of how you manage a particular situation. Dr Treat: Absolutely. So, this figure in particular is helpful in multiple ways. One is to just give a visual of what these disease trajectories are doing, because we're doing that when and we take a history from a patient. But actually, to put it into an external visual for yourself, for your team, but also perhaps for the family can be really powerful. It helps you contextualize the episode of care in which you're meeting the family right now. And it also helps, sometimes, provide some sense of alignment or point out some discrepancies about how you're viewing that child's health and quality of life as compared to how the family might be viewing it. And so, if you say, you know, it sounds like during those five years before we met, you were up here, and now we find ourselves down here, and we're kind of in the middle of the range of where I've seen this person's health status be. Do I have that right? Families feel really seen when you do that and when you can get it accurately. And it also invites a dialogue between the two parties to be able to say, well, maybe I would adjust this. I think we had good health or good quality of life in this season. But you're right, it's getting harder. It's kind of that "show, don't tell" approach of bringing together all the facts to put together the relative position of where we are now in the context of everything they've been through. Dr Smith: You know, I wonder if you could talk a little bit more about the differences between palliative care and adult patients and in children? Dr Treat: Absolutely. One of the key features in pediatrics is this kind of overriding sense of an out-of-order event in the family's life. Children are not supposed to have illness. Children are not supposed to have disability. Children are not supposed to die before their parents. And that layer of tragedy is incredibly heavy and pervasive. It's not every encounter that you have in child neurology, but it does kind of permeate some of the conversations that neurologists have with their patients, especially patients who have serious neurological disease. So that could be things like epileptic encephalopathies, birth injuries, other traumatic brain injuries down the line. In the paper, I'd go through many different categories of the types of conditions that are eligible for pediatric neuropalliative medicine, that kind of support. When we think about that layer of tragedy in the relation to where we're meeting these families, they deserve extra support, not just to think about the medicines and the treatments, but also, what can we hope for? How can we give this child the best possible life in whatever circumstance that they're in? How can we show up in whatever medical decision-making circumstances present themselves to us and feel like we've done right by this child? It's a complex task, and pediatric neural palliative medicine is evolving to be able to be in those spaces with families in a very meaningful way. Dr Smith: So, of course, one of the differences is the, you know, very important role of parents in the situation, right? Obviously, parents are involved in adult palliative care issues and family is very important. But I wonder if you can talk about specific considerations given the parent-child relationship? Dr Treat: So, pediatric neuropalliative medicine really helps facilitate discussions not just about, again, those things that we have data on, but also about what is meaningful and foundational for those families. What's possible at home, what's possible in the community. In pediatrics, parents are making decisions on behalf of their child, often as a dyad, and I don't think this gets enough attention. We know from adult literature that making decisions on behalf of someone else is different from making decisions on behalf of oneself. We call this proxy decision-making. And proxies are more likely to be conservative on behalf of someone else than they are on behalf of themselves, and they're also more likely to overestimate the tolerability of a medical intervention. So, they might say, I wouldn't want this, or, I wouldn't accept this risk on behalf of myself, or, I don't think I'd want to have to persevere through something, but on behalf of this other person, I think they can do it or I will help them through it or something else like this, or, I can't accept the risk on behalf of them. So that's not good or bad. That's just different about making a decision on behalf of oneself as compared to making a decision on behalf of someone else. When there's two people trying to be proxies on behalf of a third person, on behalf of a child, that's a really, really complex task, and it deserves support. And so, pediatric neural palliative medicine can function, then, as this neutral space, as this kind of almost coaching opportunity alongside the other medical doctors to give parents an opportunity when their minds are calm---not in the heat of the moment---to talk about how they see their child, how they've shown up themselves, what they've seen go well, what they've struggled with. And how,, then we can feel prepared for future decision making times, future high-stress encounters, about what will be important to ground them in those moments, even though we can't predict fully what those circumstances might be. Dr Smith: It sounds, you know, from talking to you and having read the article, that these sorts of issues evolve over time, right? And you have commented on this already from your very first answer. And you do describe a framework for how parents think---their mental model, I guess---of, you know, a child with a serious illness. And this sounds like appreciation of that's really important in providing care. Maybe you can talk us through that topic? Dr Treat: I refer to this concept of prognostic awareness in all of the conversations that we have with families. So, what I mean by prognostic awareness is the degree of insight that an individual has about what's currently happening with their child and what may happen in the future regarding the disease and/or the complications. And when we meet people early on in their journey, often their prognostic awareness, that sense of insight about what's going on, can be limited because it requires lived experience to build. Oftentimes time is a factor in that, we gain more lived experience over time, but it's not just time that goes into building that. It's often having a child who has a complication. Sometimes it's experiencing a hospitalization. That transfer from a cognitive understanding of what's going on, from a lived experience about what's going on, really amplifies that prognostic awareness, and it changes season by season in terms of what that family is going through and what they're willing to tolerate. Dr Smith: You introduced a new term for me, which is hyper-capableism. Can you talk about that? I found that really interesting and, you know, it reminds me a lot of the epiphanies that we've had about coma and coma prognosis. So, what's hyper-capableism? Dr Treat: Yes. In neurology, we have to be very aware of our views on ableism, on understanding how we prognosticate in relation to what we value about our abilities. And hyper-capableism refers to someone who feels very competent both cognitively and from a motor standpoint and fosters that sense of value around those two aspects to a high degree. I'm referencing that in the article with regard to medicine, because medicine, the rigors of training, the rigors of practice, require that someone has mental and motor fortitude. That neurology practice and medical practice in general can breed this attitude around the value of skills in both of those areas. And we have to be careful in order to give our patients and families the best care, to not overly project our values and our sense of what's good and bad in the world regarding ableism. Impairments can look different in different social contexts. And when the social context doesn't support an impairment, that's where people struggle. That's where people have stigma. And I think there's a lot of work that we can do in society at large to help improve accommodations for impairment so that we have less ableism in society. Dr Smith: Another term that I found really interesting kind of going back to parents is the "good parent identity." Maybe you can talk about that? Dr Treat: Good parent identity, good parent narrative, is something that is inherent to the journey when you're trying to take care of and make decisions on behalf of a child. And whether you're in a medical context or outside of a medical context, all parents have this either explicit or implicit sense of themselves about what it means to do right by their child. This comes up very poignantly in complex medical conditions because there are so many narratives about what parents ought to do on behalf of their child, and some of those roles can be in tension with one another. It's a whole lot of verbs that often fall under that identity. It's about being able to love and support and take good care of and make good decisions on behalf of someone. But it's also about protecting them from harm and treating their pain and being able to respond to them and know their cues and know these details about them. And you can't, sometimes, do multiple of those things at once. You can't give them as much safety and health as possible and also protect them from pain and suffering when they have a serious illness, when they need care in the hospital that might require a treatment that might be invasive or burdensome to them. And so, trying to be a good parent in the face of not being able to fulfill all those different verbs or ideas about what a good parent might do is a big task. And it can help to make it an explicit part of the conversation about what that family feels like their good parent roles might be in a particular situation. Dr Smith: I want to shift a little bit, Lauren, that's a really great answer. And just, you know, listening to you, your language and your tongue is incredibly positive, which is exciting. But, you know, you have talked about up and downs, and I wanted you to comment on a quote. I actually wrote it down, I'm going to read it to you, because you mentioned this early on in your article: "the heavy emotional and psychological impacts of bearing witness to suffering as a child neurologist." I think all of us, no matter how excited we are about all the therapeutic development, see patients who are suffering. And it's hard when it's a child and you're seeing a family. I wonder if you could talk a little bit about that comment and how you balance that. You're clearly- you're energized in your career, but you do have to bear witness to suffering. Dr Treat: You're right. Child neurologists do incredible work, it's an incredible, exciting field, and there are a lot of challenges that we see people face. And we see it impacts their lives in really intense ways over the course of time. We bear witness to marriages that fall apart. We bear witness to families that lose jobs or have to transition big pieces of their identity in order to care for their children. And that impacts us. And we hold the collective weight of the things that we are trying to improve but sometimes feel less efficacious than we hoped that we could around some of these aspects of people's lives. And so, pediatric neuropalliative medicine is also about supporting colleagues and being able to talk to colleagues about how the care of the patients and the really real effort that we exert on their behalf and the caring that we have in our hearts for them, how that matters. Even if the outcome doesn't change, it's something that matters for our work and for our connections with these families. It's really important. Dr Smith: I wonder, maybe we can end by learning a little bit about your journey? And maybe this is your opportunity to- I know we have students and residents who listen to us, and junior faculty. I think neuropalliative care is obviously an important issue. There's a whole Continuum issue on it---no pun intended---but what was your journey, and maybe what's your pitch? Dr Treat: I'm just going to give a little bit of a snippet from a poem by Andrea Gibson, who's a poet, that I think speaks really clearly to this. They say a difficult life is not less worth living than a gentle one. Joy is simply easier to carry than sorrow. I think that sums these things up really well, that we find a lot of meaning in the work that we do. And it's not that it's easier or harder, it's just that these things all matter. I'm going to speak now, Gordon, to your question about how I got to my journey. When I went into pediatrics and then neuro in my training, I have always loved the brain. It's always been so crucial to what I wanted to do and how I wanted to be in the world. And when I was in my training, I saw that a lot of the really impactful conversations that we were having felt like we left something out. It felt like we couldn't talk about some of the anticipated struggles that we would anticipate on a human level. We could talk about the rate and the volume of the G tube, but we couldn't talk about how this was going to impact a mother's sense of being able to nourish and bond and care for their child because we didn't have answers for those things. And as I went on in my journey, I realized that even if we don't have answers, it's still important for us to acknowledge those things and talk about them and be there for our patients in those conversations. Dr Smith: Well, Lauren, what a great way to end, and what a wonderful conversation, and what a great article. Congratulations and thank you. Dr Treat: Thank you, Gordon. It was a pleasure to be here. Dr Smith: Again today, I've been interviewing Dr Lauren Treat about her really great article on neuropalliative medicine in pediatric neurology practice. This article appears in the December 2025 Continuum issue on neuropalliative care. Be sure to check out Continuum Audio episodes from this issue and other issues. And thanks again to you, our listeners, for joining us today. Dr Monteith: This is Dr Teshamae Monteith, associate editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.

Dr. Sarah Weatherspoon, associate chief of Pediatric Neurology at Le Bonheur Children's Hospital, discusses seizure first aid, why accurate diagnosis matters and what families should know when seizures aren't well controlled.  Learn more about Sarah Weatherspoon, MD 

In this episode, Dr. Tony Ebel addresses a question that deeply concerns seizure parents: why seizures often increase during developmental leaps. Drawing from both clinical experience and his personal journey as a father, he explains how these temporary upticks can be part of neurological growth and healing, not necessarily regression. Dr. Tony breaks down the neuroscience behind neuroplasticity, increased metabolic demand, and why the nervous system can look more unstable before reorganizing more effectively. He also shares clear guidance on how to support your child during these phases, how to tell the difference between healing progress and true setbacks, and when additional medical support is needed.-----Links & ResourcesListen to the deep dive seizures episode here.Get access to our free guide to improve your child's sleep here.-----Key Topics Covered:3:00 Dr. Tony's personal story and his son's seizure journey6:00 Reframing the challenge and when an uptick may signal healing11:00 The neuroscience of neuroplasticity and temporary instability14:00 Why vulnerable nervous systems struggle more during developmental leaps17:00 Three key signs to distinguish healing progression from true regression22:00 How parents can support their child through regulation, sleep, and metabolic needs26:00 Metabolic demand and the immune system connection30:00 The vagus nerve's role in neurological stability32:00 Understanding regression as part of progression in healing36:00 Practical recap and warning signs that require medical review40:00 Closing encouragement and how to submit future questions-- Follow us on Socials: Instagram: @pxdocs Facebook: Dr. Tony Ebel & The PX Docs Network Youtube: The PX Docs For more information, visit PXDocs.com to read informative articles about the power of Neurologically-Focused Chiropractic Care. Find a PX Doc Office near me: PX DOCS DirectoryTo watch Dr. Tony's 30 min Perfect Storm Webinar: Click Here

Dr. Carole Keim welcomes pediatric neurologist and Assistant Professor in the Department of Neurology at the University of Rochester, Dr. Justin Rosati, MD, to the show to talk about pediatric neurology. They explore what he sees in children as a pediatric neurologist and what parents can look for.  Dr. Keim and Dr. Rosati discuss febrile seizures, developmental delays, epilepsy, infantile spasms, and anything neurological that can affect babies and toddlers. Dr. Rosati says that children not meeting a developmental milestone is often why parents bring them in to see him. He works to answer the question of why the child misses or is behind on the milestone and explains what it is that he looks for to see if further testing is needed. He tells Dr. Keim what red flags parents can look out for in terms of neurological conditions. He and Dr. Keim discuss febrile seizures and genetic epilepsy syndromes, as well as when seizure medications might be useful. Dr. Rosati breaks down childhood migraines, how parents can help and identify them, and exactly what neurological disorders entail. It's a wealth of information for parents wanting to know what red flags to keep in mind.Dr. Justin Rosati, MD:Dr. Justin Rosati is an Assistant Professor of Neurology at the University of Rochester. He specializes in Fetal & Neonatal Neurology as well as Clinical Neurophysiology. Dr. Rosati has a special interest in digital media and its use for education for students, residents, parents, and colleagues. He is an active medical content creator focusing on short-form videos for Instagram and TikTok. You can follow him across social media platforms @thebabybraindoc.__ Resources discussed in this episode:The Holistic Mamas Handbook is available on AmazonThe Baby Manual is also available on Amazon__ Contact Dr. Carole Keim, MDlinktree | tiktok | instagram Contact Dr. Justin Rosati, MDlinktree | instagram | University of Rochester Medicine Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Facioscapulohumeral muscular dystrophy (FSHD) is one of the most common forms of muscular dystrophy, affecting individuals across the lifespan with variable severity. Advances in genetic understanding and therapeutic development have led to an era of promising disease-modifying strategies. In this episode, Katie Grouse, MD FAAN, speaks with Renatta N. Knox, MD, PhD, author of the article “Facioscapulohumeral Muscular Dystrophy” in the Continuum® October 2025 Muscle and Neuromuscular Junction Disorders issue. Dr. Grouse is a Continuum® Audio interviewer and a clinical assistant professor at the University of California San Francisco in San Francisco, California. Dr. Knox is an assistant professor of neurology in the Division of Pediatric Neurology and Neuromuscular Section at Washington University School of Medicine in St. Louis, Missouri. Additional Resources Read the article: Facioscapulohumeral Muscular Dystrophy Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN  Full episode transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME, subscribing to the journal, and exclusive access to interviews not featured on the podcast. Dr Grouse: This is Dr Katie Grouse. Today I'm interviewing Dr Renatta Knox about her article on fascioscapulohumeral muscular dystrophy, which appears in the October 2025 Continuum issue on muscle and neuromuscular junction disorders. Welcome to the podcast, and please introduce yourself to our audience. Dr Knox: Hi Katie, thank you so much for the invitation for the audio interview. I'm looking forward to our conversation. As she mentioned, my name is Renata Knox. It's a pleasure to be here today. Dr Grouse: I'd like to start by asking, what is the key message that you hope your readers will take from your article? Dr Knox: I would say two things. The first is an appreciation and understanding of the unique genetic mechanism that leads to FSHD. And the second is the really exciting therapy landscape that we find ourselves in. So, we're hopeful that there will actually be disease-modifying therapies for FSHD soon. Dr Grouse: We're really looking forward to learning more about that. Now, before we get to that piece, could you just remind us of the clinical manifestations and features that are specific to FSHD? Dr Knox: So, one of the most unique things about FSHD that we see clinically is the pattern of weakness. So, one of the first features is that it's asymmetric. And then there are certain muscle groups that typically are affected, and that's partly where the name comes from. So, we see effects in the face, the limbs, the trunk; and so, those are some of the unique features that we see clinically. Dr Grouse: I'd love it if you could walk us through how you approach diagnosing a patient who presents with proximal weakness where FSHD is in your differential. Dr Knox: Yeah, it's a really great question. So, I would say it depends. So, I actually focus on FSHD in my clinical practice. So, many times patients are referred to me because there's a very high suspicion or there's a known family history of FSHD. So, that's one category of cases. I would say the other category of case is where it's, as you said, maybe more proximal weakness more broadly. Someone that's before me who has a known family history, they really have some of the characteristic physical features---which I'm pretty attuned to, as this is, you know, part of my subspecialty---I'll actually go directly to FSHD genetic testing. And that is one of the unique features of this disease, that the next-generation sequencing panels that are typically used for some of our other muscle diseases, FSHD is not captured on those. So, we actually have to send targeted testing for FSHD to diagnose it. So, that is one category where, again, I have a very high suspicion either based on their clinical presentation and/or a known family history, then I will actually go directly to FSHD-targeted genetic testing. In the second case, where it is one of the conditions that I'm considering among others, I will do more broad testing. So, I will get a CK level to see if there's evidence of muscle breakdown. I'll likely also do one of the next-generation sequencing panels that we have access to, which will allow us to identify, potentially, one to two hundred potential muscle diseases. And then again, if FSHD is higher on my differential in that second group of patients, then I will also send targeted FSHD-specific testing. Dr Grouse: That's really helpful. And I'm wondering if you have any thoughts about common pitfalls that you've seen when providers are trying to work this up? Dr Knox: I don't know if I would say pitfalls. I think I would acknowledge that it's challenging. My subspecialty training in neuromuscular medicine and also gene therapy. And so FSHD is pretty high on my radar. But I would say in neurology in general---and then, you know, the general medical population---,it really isn't something that many people are seeing. So, I would say what patients will communicate to us sometimes is some frustration that maybe it took time to make the diagnosis, but I just have a deep understanding that it's not something that is on many people's radars. And I think, again, it's tricky because it's not picked up on these next-generation sequencing panels, which many of us can send pretty easily. It will be missed. And I will say the biggest pitfall is, again, if you're not thinking about it and you don't send that testing, you actually- it's very difficult to diagnose it. Dr Grouse: Thank you so much for highlighting that. I think there are many people who are not aware that those different panels really aren't picking that up and that they have to test specifically. So, I think that's a great thing for all of us to keep in mind. Are there any tips or tricks to the diagnosis, other than the genetic issues that you mentioned, that sometimes can really bring this diagnosis to the forefront? Dr Knox: I think things that really tip me off to having a higher suspicion for FSHD is facial weakness that we can detect on our exam. Scapular winging---again, there's a small subset of disorders which can impact that. Someone who's presenting with foot drop, you know, with facial weakness, I think definitely about FSHD more. Also, clinically, kind of the presentation or things that they're beginning to have difficulty with is a tip-off. So, if someone is an athlete, like, they're a volleyball player or basketball player and they say, oh, I'm having difficulties, you know, with movements that require them to elevate their arm, which can be a sign of the shoulder weakness that we classically see. Or someone who says, oh, I'm having a harder time shampooing my hair or combing my hair. So those can be tip-offs again, which are basically referencing the type of weakness that they have. Another feature of FSHD which isn't necessarily as broadly appreciated is that pain and fatigue are very common. So, if someone is coming in and saying, actually, I also have a significant amount of fatigue as well or a lot of pain, that's something that can tip me off to it. Hearing loss is something that we can also see in up to 20% of patients with FSHD. So, if they are having those symptoms or saying they're ringing in their ears, these are some things that will make me begin to think about it more. Dr Grouse: Oh, really helpful. I also found it really fascinating reading some of the very FSHD-specific clinical signs, some interesting- some diagrams and pictures as well, that are very specific to the pattern of weakness that develops in FSHD. So, I encourage our listeners to check that out. But are there any highlights from those little clinical pearls that you'd like to point out? Dr Knox: I think the poly-hill sign---so, these are these literal hills that we can see in the shoulders of patients with FSHD---is pretty classic. Popeye arms, which is this older term that we still use that has to do with which muscle groups are preserved versus those that have atrophy. So that's a common feature. And then I would say, really, the asymmetry is something that is a unique feature in FSHD. And again, we did our best to provide good representative images. So again, as you mentioned, Katie, I would really encourage people to look at those images and then think about cases that they may have seen and how similar they are so they can begin to recognize those signs as well. Dr Grouse: Now going back to the genetic topic, the complex genetic underpinnings of FSHD are really well-explained in your article; and again, worth taking a look at to remind ourselves of everything that's of that pathology. Now, I was wondering though, if you could give us a brief overview of how we should approach genetic testing in a suspected case of FSHD? You mentioned some specific panels, but it does sound like there's some more complexity to it as well. Dr Knox: Yes, and I'll just kind of briefly explain that complexity. Part of the thing that we're detecting in the genetic testing is the repeat number. And so, we're actually looking for a contraction in a repeat number. So, not an expansion, which were typical for some of the diseases that we think about, the trinucleotide repeat disorders. And this is why it's not captured in the next-generation sequencing panels, because they do not currently have the ability to do that. And so, again, what the type of testing that I do really depends on my suspicion. So again, if my suspicion is very high for FSHD---they have a family history, they have the classic features---then I will actually go directly to an FSHD-specific testing, which is available from various sources. If, again, it's among different things that I'm thinking about, I will get a CK lab. I typically will also send a next-generation sequencing panel specific for muscle diseases, perhaps muscular dystrophy; again, depending on what I'm thinking about. And then I will also send in a specific FSHD genetic test as well. People are beginning to use whole-genome sequencing, which is capturing some of our true nucleotide repeat disorders and becoming more comprehensive. So, my hope is that as that becomes more standard of care---like, whole-exome sequencing can be gotten pretty routinely now---that it may be easier for us to make some of these diagnoses. Dr Grouse: Well, that's really helpful, and thanks for that overview. Now another thing that you mentioned that I thought was really interesting in your article was that patients with, you know, history of FSHD, perhaps in the family, who are pregnant and want to screen for this disease would not be able to use sort of the more common screening tests like cell-free DNA testing and may have to go to other means to do that. What is generally their route to this type of testing? Dr Knox: Yeah, great question, and really important question for family planning purposes, and it definitely comes up in clinical practice. And so again, because of the unique genetics of FSHD, you actually have to do invasive genetic testing currently to be able to test it. And so that's, you know, amnio or chorio, and then send it to a lab that can perform, again, FSHD-specific testing on the samples that are presented. And there are obviously labs that are capable of doing that and centers that are capable of doing that, but it is not picked up on the cell-free DNA panels that are being very routinely used. You or your provider has to be thinking about it to send that specific testing, similar to our patients that come into clinic and have not yet been diagnosed. Dr Grouse: Once you have the diagnosis, what are our options for therapy? I think it sounds like at this current time, it looks to be mostly supportive. What are some of the supportive care options we should keep in mind? Dr Knox: Yes, so that is definitely accurate. Care today is supportive, but again, we're very excited about the clinical trial and therapy landscape for FSHD. So, I work very closely with my physical therapy colleagues that are in clinic with me. So, we work very closely with physical and occupational therapists to help with supportive measures, adaptive measures, doing assessments, helping our patients to be able to move and exercise safely and effectively. As I mentioned, pain is very common in FSHD and so we can treat that with medications. The most common medication that we use to treat for pain in FSHD are NSAIDs. And then other than that it's really, you know, supportive measures. Do they need to see other subspecialists? There are some surgical options. Those are used very rarely to help with some of the scapular weakness, but typically it's physical therapy, occupational therapy, supportive devices. We treat the pain as we're able to, and then we work with other subspecialists to screen, monitor and support our patients to the best of our ability. Dr Grouse: Well, without further ado, I'd love to hear more about what's coming down the pipeline in clinical trials. What can we look forward to seeing, hopefully, in future years to treat these patients? Dr Knox: Yes. And so, this is actually what got me interested in the neuromuscle space in general is that, because we now for many years have known the genetic cause of many of these disorders as well as some of the underlying mechanisms, we can actually use advances in therapeutics to do what we call targeted therapies. So, rather than treating symptoms or indirect methods or doing kind of broad drug screens---which, again, still do take place and still do have their place---we actually can target mechanisms directly. And so, we know that the underlying biology of FSHD is due to this protein called DUX4 being expressed when it should not be. So, it's what we call a toxic gain of function. And so, the targeted way to address this is to suppress DUX4 expression. And so, kind of broadly speaking, what we're really excited about are a couple of products that are currently in clinical trials right now that actually caused DUX4 suppression to be suppressed. And again, these are targeted pathways. And so, again, the hope is that by doing that, we can hopefully slow the progression of the disease, potentially stop progression of the disease, and potentially reverse. Again, we don't know if that might be possible, but that is one of the hopes. Dr Grouse: Well, that's really exciting, and I know we're all looking forward to more coming down the pipeline soon, and hopefully more things that can really offer some exciting treatments for our patients with this condition. Now, a little more deep-dive into our patients who are diagnosed. You've reviewed some of the treatments currently available and hopefully may someday soon be available. Are there other things that we should be keeping in mind in this population? For instance, screenings that we should be doing for other extramuscular manifestations that we need to be thinking about? Dr Knox: I will answer that question two ways. I think something that's very important to acknowledge is the impact that these diagnoses and these conditions have on our patient practically, psychologically. One of the other unique features of FSHD is, it's autosomal-dominant. So, if it is in a family, you can have many family members who are affected, but the variability is very high. And so, you can have in the same family someone who is wheelchair-dependent, and someone else in the family with the same underlying genetics who has no signs or symptoms or is very mildly affected. And that is something that is definitely challenging for our families and patients to navigate if they're very different than their family members with the same condition. And just navigating the world with a condition that, you know, can be physically debilitating and cause changes to what they're able to do or not able to do, progression is something that's very difficult to handle. So, I think that's one set of things. And we try our best, you know, with my team and my other colleagues in the space, to support our families and patients in the best way that we can. Secondly, there is very important screening that needs to be done for this condition. So, one of the things- and the current guidelines which are actually being updated, the last update was in 2015 is all patients that undergo pulmonary function testing or PFTs. And so that's something we do at baseline and we do at least annually in my practice. Young kids who are presenting very early or patients with certain genetics that we know are more predisposed to extra muscular manifestations, we recommend screening for hearing, which is one of the manifestations, and ophthalmologic exam to look for retinovascular changes, which is one of the manifestations as well. Those are the more common ones that are typically done. There's also some evidence in pediatric patients with very severe manifestations that there may be some cognitive impacts, learning impacts. And so, that is something we're also thinking about screening and supporting our patients in that way. And again, we typically work with these patients in a multidisciplinary team depending on what manifestations and the degrees to which they're impacted by the disorder. Dr Grouse: Thank you so much for that answer. I think a lot of us forget sometimes when we get really focused on what can we do now, that we forget to kind of stop and reflect on sort of the more holistic approach. How is this affecting the patient? How is this affecting the patient's family dynamic, and what other ways are they going through life with this condition that we need to be thinking about? So, I appreciate you bringing that up. I wanted to ask, sort of based on what you're talking about and what you mentioned already, you happened to mention that what initially drew you that to this work was your interest in some of the really exciting breakthroughs in the field. Well, was there anything else that drew you to, specifically, congenital neuromuscular diseases, and FSHD in particular? Dr Knox: I'm a physician scientist by training, and so I would describe myself also as a molecular biologist. So, I love getting into the nitty gritties of disease mechanisms, what genes are doing in bodies, how they function. And so, as I mentioned earlier, in the neuromuscle space, we've known for many years the genetic cause of many of these disorders and have done great, you know, mechanistic work to kind of define why we see the disease. And then now we're at this intersection of that knowledge marrying with these really novel therapeutic approaches, gene therapy approaches, being able to intersect and then in very creative ways actually target diseases very directly. And so, I would say it really is the combination of those two things. FSHD has a really fascinating unique biology, which again, we encourage everyone to read about more in the article. That really drew me to it. I'm very interested in gene regulation, transcription. This is one of the underlying mechanisms that is gone awry in the disorder, and then that being married to advances in therapeutics. So, you could wed those two pieces of information and actually meaningfully impact patient 's lives. And again, that's the real privilege and honor to witness is how these therapies can transform lives. And I saw it happened with this one case for this one disorder when I was a resident where there was no treatment. Young children, unfortunately, would not survive the disease. And then I saw the therapy come be in development and literally change the trajectory. And this is what we're very hopeful for in the FSHD space, that wedding, this wonderful basic science research, translational research, companies working together to develop these therapies that can transform lives. It is just so beautiful to witness and see, and it's something that I get to do. You know, it's a part of my job, so it's a real privilege. Dr Grouse: Well, I have to say, it's really inspiring hearing you talk about it. And I imagine that many neurologists-in-training who are listening to this may be inspired as well and may be convinced to go into this field for that very reason. So, thank you so much for sharing all of this information with us today. I learned a lot, and I think all of our listeners have too. Dr Knox: Thank you. It's really been a pleasure. Dr Grouse: Again, today I've been interviewing Dr Renatta Knox about her article on fascioscapulohumeral muscular dystrophy, which appears in the October 2025 Continuum issue on muscle and neuromuscular junction disorders. Be sure to check out Continuum Audio episodes from this and other issues. And thank you to our listeners for joining today. Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.

This podcast discusses encephilitis. The episode was developed by Emily Kacer, first-year pediatrics resident at the McMaster University, in collaboration with Dr. Brandon Meaney, Division Head of Pediatric Neurology and an Associate Professor of Pediatrics at McMaster University. Together, they define encephalitis and identify the common infectious and autoimmune causes in pediatric population, discuss an approach to diagnosing encephalitis, compare it with meningitis, review some of the potential long-term complications of encephalitis.  There are no conflicts of interest to disclose by the authors.  

In this episode of The Pediatric Lounge podcast, Dr. Richard Fry and Dr. James Riellly discuss innovative treatments in autism care. Dr. Fry, an expert in pediatric neurodevelopmental medicine, emphasizes the role of folate, mitochondrial dysfunction, and autoantibodies in autism.  Dr. Riley shares clinical anecdotes attesting to these benefits and underscores the importance of comprehensive care, including diet and sleep. 00:00 Introduction to the Pediatric Lounge Podcast 00:38 Meet the Guests: Dr. Richard Fry and Dr. James Riley 02:48 Dr. Fry's Journey into Pediatric Neurology and Autism 04:57 Discovering the Folate Connection in Autism09:14 Dr. Riley's Path to Nutrition and Autism Care 12:11 The Role of Folate in Neurodevelopmental Disorders 16:48 Challenges and Solutions in Autism Treatment 19:44 Understanding the Complexities of Autism and Nutrition29:57 The Importance of Comprehensive Medical Evaluation in Autism31:41 Complexities of Pediatric Neurology 33:06 Approaches to Nonverbal Children 33:50 Folinic Acid and Autism 35:37 Success Stories with Leucovorin39:13 Challenges in Pediatric Practice 45:54 Empowering Parents and Pediatricians51:59 Concluding Thoughts and ReflectionsNeurobiological Rationale and Effects on the BrainLeucovorin is a reduced form of folate that bypasses the folate receptor alpha, the primary transporter of folate across the blood-brain barrier. In ASD, a high prevalence of FRAA (up to 75%) has been documented, leading to impaired cerebral folate transport and subsequent deficiency despite normal serum folate levels.[1][2] Leucovorin utilizes the reduced folate carrier to restore central nervous system folate levels, thereby addressing a key pathophysiological mechanism in a subset of children with ASD.[1][2]Treatment of Folate Metabolism Abnormalities in Autism Spectrum Disorder. Frye RE, Rossignol DA, Scahill L, et al. Seminars in Pediatric Neurology. 2020;35:100835. doi:10.1016/j.spen.2020.100835.Efficacy of Oral Folinic Acid Supplementation in Children With Autism Spectrum Disorder: A Randomized Double-Blind, Placebo-Controlled Trial. Panda PK, Sharawat IK, Saha S, et al. European Journal of Pediatrics. 2024;183(11):4827-4835. doi:10.1007/s00431-024-05762-6.Support the show

Reference:  Othman AA, et al. Combined ketamine and midazolam vs. midazolam alone for initial treatment of pediatric generalized convulsive status epilepticus (Ket-Mid study): A randomized controlled trial. Pediatric Neurology. June 2025 Date: May 27, 2025 Guest Skeptic: Dr. James Chamberlain is a pediatric emergency medicine attending physician at Children's National Hospital in Washington, DC where […] The post SGEM#482: Seize the Day with Ketamine and Midazolam for Pediatric Status Epilepticus first appeared on The Skeptics Guide to Emergency Medicine.

About the Guest(s): Dr. Laura Standridge: Dr. Laura Standridge is a prominent functional chiropractor known for her expertise in pediatric neurological development and genetic disorders. She is board certified in neurofeedback and specializes in approaches that focus on neurodevelopmental assessments, particularly concerning mitochondrial function and primitive reflexes. Dr. Standridge has gained attention for her work with rare neurodegenerative disorders, particularly BPAN, following her son's diagnosis with the disease. Her professional journey is marked by a dedication to understanding and improving neurological health through innovative methods in functional and integrative healthcare. Episode Summary: In this enlightening episode of Functional Health Radio, Dr. Kristin Hieshetter delves deep into the pressing health crises in America, revealing that the country's life expectancy has not only plateaued but declined for both men and women. Despite the high per capita healthcare expenditure, conditions like heart disease and cancer remain prevalent, and children are increasingly diagnosed with chronic diseases. The discussion transitions into a heartfelt narrative with Dr. Laura Standridge, a functional chiropractor passionately occupied with her son Laird's rare neurodegenerative disease known as BPAN (Beta-propeller Protein-Associated Neurodegeneration). BPAN, characterized by iron accumulation in the brain, is a daunting diagnosis for any family, but Dr. Standridge shares her proactive approach to defy the medical script of decline. Employing advanced genetic testing and leveraging her deep understanding of functional health principles, Dr. Standridge explores comprehensive interventions that have led to remarkable outcomes for Laird. From dietary adjustments to specialized neurodevelopmental therapies and state-of-the-art medical interventions, Dr. Standridge's narrative underscores a hopeful perspective—not only sharing insights about BPAN but also reflecting innovative applications of functional health practices. This episode highlights how a blend of cutting-edge science and compassionate care can write new chapters in health and wellness narratives. Key Takeaways: BPAN Disease Insight: BPAN is a rare neurodegenerative disorder that causes abnormal iron accumulation in the brain, significantly impairing mitochondrial function and autophagy. Unique Case of Laird: Laird defies the typical BPAN trajectory through a tailored combination of nutritional strategies, functional therapies, and mitochondrial enhancement techniques. Importance of Nutrition: Laird's diet, free of gluten and inflammatory foods, supports brain health by preventing autoimmune responses that can exacerbate neurological damage. Integrative Approaches: Utilization of genetic testing and innovative therapies, like low-level laser therapy, provides neuroprotective benefits and enhances Laird's quality of life. Collaborative Healthcare: Dr. Standridge exemplifies the power of interdisciplinary collaboration, uniting various specialists to support a functional health-driven roadmap for Laird. Notable Quotes: "We are walking around in the most amazing, intelligent, responsive, adapting and aware system in the world, the human. Let's bring it to its fullest potential." - Dr. Kristin Hieshetter "It doesn't matter what the label is…I'm much more interested in how you are functioning and not what somebody from the outside might call you." - Dr. Laura Standridge "We waited and we waited and we waited some more and finally received this diagnosis." - Dr. Laura Standridge "The brain is built on the postural system…and so there is this amazing order of neurological development whether you have a genetic difference or not." - Dr. Laura Standridge "Together, we'll be the change that we wish to see in the world." - Dr. Kristin Hieshetter Resources: Learn more about BPAN and related genetic testing at the CDC Vital Statistics Report: www.cdc.gov For insights into functional chiropractic care and Dr. Laura Standridge's approaches, visit Functional Health Mastery Stay informed with the World Economic Forum's health expenditure data: www.weforum.org Functional Health Mastery Group Listen to the full episode to dive deeper into the revolutionary approaches that Dr. Laura Standridge and Dr. Kristin Hieshetter share in tackling BPAN, and stay tuned for more inspiring stories and informative discussions on Functional Health Radio.

Dr. Richard Haier is an emeritus professor of Pediatric Neurology at UC Irvine, who spent his career studying the neuroscience of intelligence. Over the course of his career, Haier has come to believe in the existence of a “g-factor,” a measurable quantity of broad spectrum intelligence that is universally predictive of success in all cultures. He also believes that intelligence is a fixed characteristic, and that it's possible to predict someone's intelligence by watching how their brain works when trying to solve a puzzle. We sit down with him to figure out how far one can take this theory of intelligence before running headlong into a heartless social darwinism, why intelligence research feels so creepy, if IQ tests are actually measuring what we think they're measuring, if intelligence is really the thing that we should be optimizing for, and if it's possible for technology to make us dumber. Don't miss the historic cosmology summit in Portugal this summer!!! DEMYSTICON 2025 ANNUAL MEETING June 12-16: https://demystifysci.com/demysticon-2025 PATREON: get episodes early + join our weekly Patron Chat https://bit.ly/3lcAasB MERCH: Rock some DemystifySci gear : https://demystifysci.myspreadshop.com/all AMAZON: Do your shopping through this link: https://amzn.to/3YyoT98 SUBSTACK: https://substack.com/@UCqV4_7i9h1_V7hY48eZZSLw@demystifysci 00:00 Go! 00:09:28 Flynn Effect and G Factor 00:15:40 Testing, Practice, and Intelligence 00:26:58 The Relationship Between Intelligence, Motivation, and Test Scores 00:31:09 Heritability and Societal Implications of Intelligence 00:35:51 The Social Value of Intelligence Versus Athletic Ability 00:41:54 IQ Levels and Educational Attainment 00:48:03 The Dilution of College Degrees 00:53:07 Educational System Critique 00:57:24 Intelligence and Occupational Success 01:01:40 Bureaucracy and Talent in Academia 01:06:13 Intelligence and Personal Success 01:19:20 Enhancing Intelligence through Drugs 01:25:28 Brain Efficiency and Intelligence 01:31:12 Tetris Study and Brain Efficiency 01:44:20 Predicting Intelligence through Brain Imaging 01:49:58 Brain Structure and Cognitive Prediction 01:52:00 Challenges in Enhancing Intelligence 02:04:22 Environmental and Genetic Interplay 02:14:02 Understanding Autism and Intelligence 02:19:56 Artificial Intelligence vs. Human Intelligence 02:28:21 Technology's Impact on Skill Development 02:32:55 Flynn Effect and Educational Implications 02:39:24 Technology and Its Impact on Children 02:45:08 Societal Roles and Intelligence Levels 02:48:09 Meaning and Societal Functionality #IQTests, #Neuroscience, #intelligence, #iqtest, #ArtificialIntelligence, #HumanIntelligence, #CognitiveScience, #BrainFunction, #iq , #Neuroimaging, #AIvsHumans, #TechImpact, #philosophypodcast, #sciencepodcast, #longformpodcast Check our short-films channel, @DemystifySci: https://www.youtube.com/c/DemystifyingScience AND our material science investigations of atomics, @MaterialAtomics https://www.youtube.com/@MaterialAtomics Join our mailing list https://bit.ly/3v3kz2S PODCAST INFO: Anastasia completed her PhD studying bioelectricity at Columbia University. When not talking to brilliant people or making movies, she spends her time painting, reading, and guiding backcountry excursions. Shilo also did his PhD at Columbia studying the elastic properties of molecular water. When he's not in the film studio, he's exploring sound in music. They are both freelance professors at various universities. - Blog: http://DemystifySci.com/blog - RSS: https://anchor.fm/s/2be66934/podcast/rss - Donate: https://bit.ly/3wkPqaD - Swag: https://bit.ly/2PXdC2y SOCIAL: - Discord: https://discord.gg/MJzKT8CQub - Facebook: https://www.facebook.com/groups/DemystifySci - Instagram: https://www.instagram.com/DemystifySci/ - Twitter: https://twitter.com/DemystifySci MUSIC: -Shilo Delay: https://g.co/kgs/oty671

Ready to diversify outside the stock market? EquityMultiple brings you streamlined real estate investing. Access vetted, cash-flowing opportunities from anywhere. Start today, with just $5K, at equitymultiple.com_________________Dr. Kristine Goins and Dr. Christopher J. Allen discuss the epidemic of sleep deprivation among physicians. Dr. Allen highlights how long shifts, irregular schedules, and cultural expectations in medicine often lead to chronic burnout.He provides insightful tips, such as maintaining consistent wake times, keeping a sleep log, and prioritizing restorative rest. He also addresses travel-related sleep disruptions and the effects of "sleep debt," explaining that while recovery is possible, it requires consistency and patience. Dr. Allen advocates seeking help for persistent issues and stresses that sleep is fundamental to effective caregiving.BioDr. Christopher J. Allen is a board-certified specialist in Sleep Medicine for both children and adults, as well as Pediatric Neurology. He received his training at the University of Michigan, the University of Chicago, and is currently the CEO and Lead Physician of Quality Sleep and Neurology PC, located in Saginaw, Michigan.A proud alumnus of Howard University and a certified pediatric neurologist, Dr. Allen is deeply passionate about neurology, with an even greater dedication to sleep medicine. His mission is to ensure that everyone has access to quality sleep, recognizing its vital role in overall health. He is a staunch advocate for prioritizing rest in a world where it is often undervalued, playfully referring to himself as a “sleep superhero” on a mission to improve sleep health.Beyond his professional life, Dr. Allen is an enthusiastic Raiders fan, a spirited karaoke performer, and a dance enthusiast.Website:https://www.qualitysleepandneurology.com/Socials.Instagram: https://www.instagram.com/sleepdrchrisFacebook: https://web.facebook.com/profile.php?id=100093550283321Youtube: https://www.youtube.com/@SleepDrChris  Dr. Kristine Goins' BioFind more about Dr. Goins here: https://www.physiciansguidetodoctoring.com/drgoins   Did you know…?You can also be a guest on our show. Please email me at brad@physiciansguidetodoctoring.com to connect or visit www.physiciansguidetodoctoring.com to learn more about the show!Socials:@physiciansguidetodoctoring on FB @physicianguidetodoctoring on YouTube@physiciansguide on Instagram and Twitter Visit www.physiciansguidetodoctoring.com to connect, dive deeper, and keep the conversation going. Let's grow! Disclaimer:This podcast is for informational purposes only and is not a substitute for professional medical, financial, or legal advice. Always consult a qualified professional for personalized guidance.

Jennifer is a true NP rockstar, creating a pediatric neurology clinic just two weeks ago and building her patient base exponentially since then. After a tenure at the first children's hospital in the state of Montana, she's taken the skills she's learned in this fascinating field and embarked on a business development journey. Today, she consults with Justin on how to get the word out about this practice and heal children in need across the nation.  In this episode, we weigh the importance of both free and paid modes of marketing content distribution. What are the best ways to get the word out without breaking the bank? Jennifer learns how far face to face interaction can truly go, and areas to focus on when attracting a solid base of loyal patients. Jennifer's story shows that the Elite NP model can be applied to virtually any practice in the field of medicine, and that success can be achieved with just a few simple strategies.  

Being a teenager is hard. So, imagine for a moment that in addition to everything else that teenagers have to endure, you're a teenager who's been diagnosed with MS. Your ability to participate in after-school activities or just hang out with your friends is impacted by MS-related fatigue. The typical adolescent anxiety over something someone posted on social media evolves into depression. And cognitive issues begin to make it harder for you in the classroom. This is an unfortunate reality for many adolescents who are living with MS. Joining me to discuss how MS affects adolescents and how families can help manage MS is Dr. Ann Yeh. Dr. Yeh is a Professor of Pediatric Neurology at the University of Toronto and the director of the MS and Neuroinflammatory Disorders Program and Fellowship Program at the University of Toronto's Hospital for Sick Children, known as SickKids.  We'll also tell you about a new online resource for MS care partners. We'll share the results of a study that explored how different symptom management responsibilities impact MS care partners. We'll share details of a study that demonstrated positive results in improving MS-related fatigue. We'll tell you about the discovery of a plant-based molecule that is showing promise in promoting myelin repair. And we're sharing surprising research results that have more than doubled the prevalence of MS in Australia. We have a lot to talk about! Are you ready for RealTalk MS??! This Week: Managing Teenage MS  :22 November is National Family Caregivers Month  1:47 You're invited to preview MS Care Partner Connection  3:40 A study reveals the most challenging MS symptoms for care partners to manage  6:33 Study results show Modafinil and cognitive behavioral therapy are both effective in managing MS fatigue  7:25 Researchers discover a plant-based molecule that may be effective in promoting myelin repair  9:46 Prevalence of MS in Australia more than doubled over an 11-year period   12:54 Dr. Ann Yeh discusses the challenges of MS among adolescents  16:05 Share this episode  31:15 Have you downloaded the free RealTalk MS app?  31:36 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/375 ADD YOUR VOICE TO THE CONVERSATION I've always considered the RealTalk MS podcast a conversation. This is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com The MS Care Partner Connection https://mscarepartnerconnection.com Addressing the Needs of Multiple Sclerosis Caregivers from Diagnosis Onward: The Development of a Comprehensive Online Caregiver Protocol https://meridian.allenpress.com/ijmsc/article/25/6/273/496788/Addressing-the-Needs-of-Multiple-Sclerosis STUDY: Symptom Management Among Multiple Sclerosis Care Partners in Canada https://meridian.allenpress.com/ijmsc/article/25/6/281/496792/Symptom-Management-Among-Multiple-Sclerosis-Care STUDY: Comparative Effectiveness of Cognitive Behavioural Therapy, Modafinil, and Their Combination for Treating Fatigue in Multiple Sclerosis (COMBO-MS): A Randomised, Statistician-Blinded, Parallel-Arm Trial https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(24)00354-5/abstract STUDY: Distinct Chemical Structures Inhibit the CEMIP Hyaluronidase and Promote Oligodendrocyte Progenitor Cell Maturationhttps://www.jbc.org/article/S0021-9258(24)02418-9/fulltext STUDY: Significantly Increasing Multiple Sclerosis Prevalence in Australia from 2010 to 2021 https://journals.sagepub.com/doi/10.1177/13524585241265890 Join the RealTalk MS Facebook Group https://facebook.com/groups/realtalkms Download the RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 Download the RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 375 Guest: Dr. Ann Yeh Privacy Policy

Children with Neurological complaints represent a significant portion of what we see in the Peds ED. From Status Epilepticus to febrile seizures to the child who (maybe) had a seizure at home. This is a discussion I had with Dr. Amy Goldstein, a Pediatric Neurologist at CHOP.   Please consider contributing to PEM Rules at https://ko-fi.com/pemrules And check out www.pemrules.com  Copyright PEM Rules LLC DISCLAIMER By listening to this podcast, you agree not to use these resources as medical advice to treat any medical conditions in either yourself or others, including, but not limited to, patients that you are treating. Consult your own physician for any medical issues that you may be having. This entire disclaimer also applies to any guests or contributors to the podcast or website. Under no circumstances shall PEM Rules, the PEM Rules podcast or any guests or affiliated entities be responsible for damages arising from their use. This podcast should not be used in any legal capacity whatsoever, including, but not limited to, establishing “standard of care” in a legal sense or as a basis for expert witness testimony. No guarantee is given regarding the accuracy of any statements or opinions made on the website or in the podcast.  

In this episode, we dive into the fascinating intersection of artificial intelligence and pediatric neurology. Our guest shares how they became interested in AI's role in healthcare and discusses how AI is being utilized to enhance diagnostic accuracy, especially in neurodevelopmental pediatrics. We explore how these advancements are improving access to care in resource-limited settings and the impact of early diagnosis on long-term outcomes for conditions like autism. Join us as we uncover the latest technological innovations transforming pediatric healthcare, the potential of AI to personalize treatment plans for children, and the concerns surrounding the widespread use of AI in medicine. Dr. Sharief Taraman, is dual board-certified in Neurology with special qualifications in Child Neurology from the American Board of Psychiatry and Neurology and Clinical Informatics from the American Board of Preventive Medicine. Dr. Taraman was the former Division Chief of Pediatric Neurology at Children's Health of Orange County and University of California-Irvine. He remains an active member of the medical staff and the Sharon Disney Lund Medical Intelligence, Information, Investigation, & Innovation Institute at CHOC. He is a Health Sciences Associate Clinical Professor at UC Irvine School of Medicine in the Department of Pediatrics and Affiliate Professor at Chapman University, Dale E. and Sarah Ann Fowler School of Engineering. Dr. Taraman is active in the community as the past president of the American Academy of Pediatrics (AAP) Orange County Chapter, board member of AAP-California, and committee member for the development of the AAP National CHILD health registry. He also serves on the Irvine Unified School District Medical Advisory Board, volunteers for the Capistrano Unified School District and with Girl Scouts of Orange County. Recognized globally as an innovator and specifically an advocate in the field of pediatrics, Dr. Taraman has been involved with the development of three FDA designated breakthrough devices, awardee of the prestigious National Capital Consortium for Pediatric Device Innovation grant, and is an advisor to Board of Directors for the International Society for Pediatric Innovation. He is the Chief Executive Officer at Cognoa and formerly served as the Chief Medical Officer leading the clinical trials that led to the FDA authorization of Cognoa's lead product, Canvas Dx, the first and only FDA authorized diagnostic device for autism for children 18-72 months old with concern for developmental delay. Dr. Taraman graduated Magna Cum Laude from the University of Michigan having majored in Biochemistry. He completed his medical education at Wayne State University School of Medicine and went on to complete residency and fellowship training in Pediatrics and Pediatric Neurology at the Detroit Medical Center and Children's Hospital of Michigan. He continued professional development through the University of California, Irvine - The Paul Merage School of Business with certifications in Leadership for Healthcare Transformation & Physician Leadership. https://cognoa.com/ _________________________________________________ Sponsor the JOWMA Podcast! Email digitalcontent@jowma.org Become a JOWMA Member! www.jowma.org Follow us on Instagram! www.instagram.com/JOWMA_org Follow us on Twitter!www.twitter.com/JOWMA_med Follow us on Facebook! https://www.facebook.com/JOWMAorg Stay up-to-date with JOWMA news! Sign up for the JOWMA newsletter! https://jowma.us6.list-manage.com/subscribe?u=9b4e9beb287874f9dc7f80289&id=ea3ef44644&mc_cid=dfb442d2a7&mc_eid=e9eee6e41e

In this episode, we dive into the fascinating intersection of artificial intelligence and pediatric neurology. Dr. Taraman shares how he became interested in AI's role in healthcare and discusses how AI is being utilized to enhance diagnostic accuracy, especially in neurodevelopmental pediatrics. We explore how these advancements are improving access to care in resource-limited settings and the impact of early diagnosis on long-term outcomes for conditions like autism.Dr. Sharief Taraman, is dual board-certified in Neurology with special qualifications in Child Neurology from the American Board of Psychiatry and Neurology and Clinical Informatics from the American Board of Preventive Medicine.Dr. Taraman was the former Division Chief of Pediatric Neurology at Children's Health of Orange County and University of California-Irvine. He remains an active member of the medical staff and the Sharon Disney Lund Medical Intelligence, Information, Investigation, & Innovation Institute at CHOC.He is a Health Sciences Associate Clinical Professor at UC Irvine School of Medicine in the Department of Pediatrics and Affiliate Professor at Chapman University, Dale E. and Sarah Ann Fowler School of Engineering.Dr. Taraman is active in the community as the past president of the American Academy of Pediatrics (AAP) Orange County Chapter, board member of AAP-California, and committee member for the development of the AAP National CHILD health registry. He also serves on the Irvine Unified School District Medical Advisory Board, volunteers for the Capistrano Unified School District and with Girl Scouts of Orange County.Recognized globally as an innovator and specifically an advocate in the field of pediatrics, Dr. Taraman has been involved with the development of three FDA designated breakthrough devices, awardee of the prestigious National Capital Consortium for Pediatric Device Innovation grant, and is an advisor to Board of Directors for the International Society for Pediatric Innovation.He is the Chief Executive Officer at Cognoa and formerly served as the Chief Medical Officer leading the clinical trials that led to the FDA authorization of Cognoa's lead product, Canvas Dx, the first and only FDA authorized diagnostic device for autism for children 18-72 months old with concern for developmental delay.Dr. Taraman graduated Magna Cum Laude from the University of Michigan having majored in Biochemistry. He completed his medical education at Wayne State University School of Medicine and went on to complete residency and fellowship training in Pediatrics and Pediatric Neurology at the Detroit Medical Center and Children's Hospital of Michigan. He continued professional development through the University of California, Irvine - The Paul Merage School of Business with certifications in Leadership for Healthcare Transformation & Physician Leadership.https://cognoa.com/This week's episode is sponsored by Toveedo! The Jewish videos your kids love, all in one happy place. Use code JOWMA10 for $10 off at ⁠⁠⁠https://toveedo.com/⁠⁠⁠! _________________________________________________​Sponsor the JOWMA Podcast! Email digitalcontent@jowma.org​Become a JOWMA Member! www.jowma.org ​Follow us on Instagram! www.instagram.com/JOWMA_org ​Follow us on Twitter!www.twitter.com/JOWMA_med ​Follow us on Facebook! https://www.facebook.com/JOWMAorg​Stay up-to-date with JOWMA news! Sign up for the JOWMA newsletter! https://jowma.us6.list-manage.com/subscribe?u=9b4e9beb287874f9dc7f80289&id=ea3ef44644&mc_cid=dfb442d2a7&mc_eid=e9eee6e41e

Drawing on eight decades of learning. Dr. Mark Scher shares his thoughts on the importance of staying curious, acknowledging and understanding disparity, and the power of an interdisciplinary approach. Dr. Mark Scher studied fetal/neonatal neurology (FNN) at the University of Rochester, followed by four years at SUNY/Downstate Medical School. He completed his pediatrics residency at Cornell/New York Hospital Pediatrics, followed by a neurology/pediatric neurology/neurophysiology fellowship at the University of Minnesota and neonatal neurology research at Stanford University. His career included time at the University of Pittsburgh, Magee-Women's Hospital and the Children's Hospital of Pittsburgh, and as Division Chief of Pediatric Neurology at Rainbow Babies and Children's Hospital in Ohio, establishing a second FNN program at the University Hospitals of Cleveland. Dr. Scher was a tenured full professor of Pediatric and Neurology at Case Western Reserve University, transitioning to Emeritus Scholar and Professor in 2020. Dr. Scher is known for national and international research collaborations and organizational work, including with the Newborn Brain Society. He's authored more than 190 peer-reviewed publications (with several more currently under review) as well as 46 book chapters. Small Brains, Big Dreams is a podcast created by the Newborn Brain Society, in partnership with the Canadian Premature Babies Foundation, and hosted by preemie parent & journalist, Jenna Morton.The Newborn Brain Society is a non-profit organization supporting a world in which all newborns have access to and receive the optimal brain care. We promote international, multi-disciplinary collaboration, education, and innovation among clinicians, scientists, and parents.Connect with us at newbornbrainsociety.org, on Facebook @NewbornBrainSociety, and on Twitter @NewbornBrains.If you've enjoyed this episode, please rate, share & subscribe.

Drs. Braham, Rogu, and Bravo have a fascinating real conversation about Digital Therapeutics. The intersection of digital innovations in pediatric healthcare with a focus on diagnosing and treating autism using AI technology like Canvas DX. It delves into challenges such as scarce specialists, early intervention's significance, regulatory processes, and the evolving role of pediatricians. Additionally, it addresses broader healthcare challenges, including insurance reimbursement complexities, policy considerations, and the pivotal role of collaboration and equity in improving patient outcomes. Dr. Sharief Taraman is the CEO of Cognoa, a leading pediatric behavioral health and data company developing AI-based technologies to enable early and equitable diagnosis and care for children living with developmental and behavioral health conditions.00:00 Welcome and Introduction to Pediatric Innovation Sessions00:33 Introducing Dr. Sharif Taraman: A Journey from Pediatric Neurology to Health Tech Leadership02:28 Exploring the Brain's Complexity and Digital Therapeutics04:21 The Evolution and Impact of Digital Diagnostics and Therapeutics07:05 Navigating the FDA Process and Addressing Pediatric Research Challenges14:01 The Real-World Application of Digital Health Tools in Pediatrics20:51 Addressing the Challenges of Pediatric Healthcare Delivery26:36 The Future of Pediatric Care: Digital Solutions and Systemic Changes32:24 Advocating for Early Prevention and the Role of Primary Care in Pediatric Health40:01 Understanding Care Coordination and the Importance of Early Detection41:13 Exploring the Multifaceted World of Care Coordination43:10 The Impact of Insurance in Care Coordination44:28 Navigating AI and Bias in Healthcare47:48 Innovating Autism Diagnosis with CanvasDX52:19 Challenges and Solutions in Medicaid Coverage01:05:37 The Future of Pediatric Care and Digital HealthSupport the show

An interview with Diana Cejas, MD, MPH (she/her), author, pediatric neurologist and assistant professor of child neurology at the University of North Carolina School of Medicine and at the Carolina Institute of Developmental Disabilities. Reading discussed: https://www.kevinmd.com/2019/06/to-struggling-medical-students-meet-the-physician-who-conquered-the-nos.html https://www.neurologylive.com/view/expanding-diversity-neurology-inclusive-communication-accessibility-diana-cejas Why This Doctor Is Fighting for Her Patients' Pain to Be Taken More Seriously | Teen Vogue

Well Said has invited Dr. Sanjeev Kothare, Director of the Division of Pediatric Neurology at Cohen Children's Medical Center, where he also serves as a Senior Epileptologist and Co-Director of the Pediatric Sleep Program. Dr. Kothare is also the Director of the Pediatric Neurology Service Line for Northwell Health and a Professor of Pediatrics & Neurology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. Today, we will be talking about the history, causes, warning signs, symptoms and more of autism spectrum disorder.

A conversation with  with Rohit Marawar, associate professor of neurology at Wayne State University. (Note: Recorded in Fall 2023)

Dr. Bhooma Aravamuthan, assistant professor, pediatric neurologist and researcher at Washington University in St. Louis, opens up about her personal experiences as a woman in medicine dealing with issues of infertility and abortion. 

Dr. Sonika Agarwal, neonatal neurologist from Children's Hospital of Philadelphia, discusses why laws against abortion affect us in pediatric neurology.

This episode's Community Champion Sponsor is Ossur. To learn more about their ‘Responsible for Tomorrow' Sustainability Campaign, and how you can get involved: CLICK HERE---Episode Overview: What will it take to shatter systemic barriers obstructing timely and equitable pediatric care? According to our next guest, Dr. Sharief Taraman, Chief Executive Officer of Cognoa, it starts with responsible AI adoption designed to uplift all patients. As creators of the first and only FDA-authorized diagnostic for autism, Cognoa continues pioneering digital health solutions upholding diversity, cost savings, and care team empowerment. While together, Dr. Taraman passionately shares Cognoa's mission of democratizing quality care, how their autism diagnostic is dissolving geographic and financial obstacles through telehealth accessibility, and why he urges investors to back ventures tackling pediatric device gaps spanning ADHD, anxiety, speech impediments, and more. Join us as Dr. Taraman shares why he and his team at Cognoa are so dedicated to unlocking equitable pediatric care. Lets go! Episode Highlights:How Cognoa launched 1st ever FDA-authorized diagnostic test for autismExtracting digital biomarkers from parental questionnaires and child observation videosReducing disparities by maintaining high accuracy across patient demographicsAuto-generating necessary evaluation documentation to alleviate administrative burdensCognoa's pursuit to earn breakthrough designation for condensed 6-week autism behavioral therapyAbout our Guest: Dr. Sharief Taraman, MD, DABPN, DABPM, FAAP, is dual board-certified in Neurology with special qualifications in Child Neurology from the American Board of Psychiatry and Neurology and Clinical Informatics from the American Board of Preventive Medicine. He formerly served as the Division Chief of Pediatric Neurology for the CHOC Children's Specialists Pediatric Subspecialty Faculty and is a Clinical Associate Professor of Pediatrics at UC Irvine School of Medicine. Dr. Taraman is the Chief Executive Officer of Cognoa, a leading early childhood development and pediatric behavioral health company, creator of the first and only FDAauthorized diagnostic for autism and early, rapid developmental health evaluation, designed to increase childhood access to life-changing early intervention and treatment of behavioral health conditions. Links Supporting This Episode:Cognoa Website: CLICK HEREDr. Sharief Taraman LinkedIn page: CLICK HERECognia LinkedIn page: CLICK HERE Mike Biselli LinkedIn page: CLICK HEREMike Biselli Twitter page: CLICK HEREVisit our website: CLICK HERESubscribe to newsletter: CLICK HEREGuest nomination form: CLICK HERE

Welcome back to another episode of our podcast dedicated to exploring the latest in stroke research, treatment, and stories of resilience. I'm your host, Amy Quinn, and today, we have an incredible guest joining us - a true expert in the field. I'm thrilled to welcome Stuart Fraser, Assistant Professor in Pediatric Neurology and the Director of the Pediatric Stroke Program here at the stroke institute. Dr. Fraser joined students at the McGovern Medical School for Stroke Grand Rounds and we asked Dr. Fraser to stick around for a follow up interview with our stroke fellow, Carlos De La Garza. Pediatric stroke is an area that often doesn't get the attention it deserves, so I'm excited for this episode, to shed light on the advancements and opportunities for improving outcomes. It's insightful, refreshing, and a great listen for students and trainees who, for all the right reasons, get nervous when they hear anything relating to pediatrics. 

Join us for the 30th episode of Your Child's Brain. In this episode, we reflect back on the topics that we discussed over the past 2 ½ years and talk about the progress that has been made in understanding and treating disorders of the developing brain and nervous system. Dr. Brad Schlaggar, president and CEO of Kennedy Krieger, is joined by his colleague Dr. Ali Fatemi, a pediatric neurologist and neuroscientist, who, in addition to serving as Chief Medical Officer at Kennedy Krieger, holds the Blum-Moser Endowed Chair in Pediatric Neurology at Kennedy Krieger, and leads the Moser Center for Leukodystrophies at Kennedy Krieger. Dr. Fatemi is also professor of neurology and pediatrics at the Johns Hopkins University School of Medicine.   Links to visit: Rare Disease Network https://www.rarediseasesnetwork.org National Organization for Rare Disorders (NORD) https://rarediseases.org/ Eunice Kennedy Shriver Intellectual & Developmental Disabilities Research Centers (EKS-IDDRCs) https://www.nichd.nih.gov/research/supported/eksiddrc Kennedy Krieger Intellectual & Developmental Disabilities Research Center https://www.kennedykrieger.org/iddrcSee omnystudio.com/listener for privacy information.

As children get set to return to school across the country, Dr. Niamh Lynch Pediatric Consultant with a special interest in Pediatric Neurology tells us how we can prepare to deal with all of those inevitable winter sicknesses.

Dr. Christy interviews Dr. Robert Sebunya, Pediatric Neurologist in Kampala, Uganda and 2022 recipient of the Child Neurology Society's Bernard D'Souza International Fellowship Award.

Dr. Conner Bor runs a successful pediatric neurology practice in Phoenix, AZ. Learn how he is helping make a difference in the lives of families and children suffering with developmental and brain health issues. If you are interested in children's health, Dr. Bor is someone to follow.   https://neuroactivecenter.com/about/ https://www.instagram.com/dr.connerbor/?hl=en

Dr. Z Paige Lerario (they/them), vascular neurologist and transgender activist currently at the Fordham Graduate School of Social Services, and Gabriel Glissmeyer (he/him), Project Specialist at the National LGBT Cancer Network in Salt Lake City, Utah, talk about involving transgender and gender diverse patients in research, and supporting our gender diverse colleagues. 

Differential Diagnosis & Management Approach of common childhood seizures including some genetic & hereditary subtypes , like benign rollandic, juvenile myoclonic and childhood absence seizure; we finish with a DDxing of childhood hemiplegia. Please make sure you have reviewed our episode on febrile seizure before this one.

In this Part 1 episode of a very special "live" community event taking place at Yanni's, Drew Schlosberg and his co-host, Isabella Pihas, sit down with both Jong Rho, M.D., the Chief of the Division of Pediatric Neurology at Rady Children's Hospital, as well as Professor of Neurosciences, Pediatrics & Pharmacology at UCSD, and Denise Pihas, the co-founder of Yanni's, a supporter of the Pediatric Inflammatory Brain Disorder program.

Livehealthy editor Ann Marie McQueen interviews Dr Arif Khan, a specialist in pediatric neurology and a consultant and director at Burjeel Medical City in Abu Dhabi. He also founded the first comprehensive children's neuroscience center in the UAE, called Neuropedia. We talk all about what happens before, during and after an autism spectrum disorder diagnosis, the rise of ADHD, and what he sees as the number one problem for all children's brains: screen time. This...

A seizure sounds like a scary event for any parent to witness in their child, but it's important to understand that a seizure doesn't necessarily mean there's a scary diagnosis in a child's future. Kenneth Habetz, MD of Our Lady of Lourdes is a pediatric neurologist and has a focus on childhood epilepsy. Dr. Habetz joins us on ParentingU to explain what a seizure is; how they are different to epilepsy; and what to do if your child has a seizure. Many parents have concerns about seizures in children—this episode has a lot of answers. Childhood Seizure Questions Answered on this Episode Does having a seizure mean a child has epilepsy? What should I do if my child has a seizure? What is a febrile seizure? What causes seizures? Do kids outgrow seizures? Is medication the only treatment for seizures? Does sugar cause seizures? Why should I video my child having a seizure? Seizure Resources for You Habetz likes some of the resources available on the Epilepsy Foundation website If your child is having a seizure, Dr. Habetz says to place the child on their side; DO NOT put anything in their mouth Habetz welcomes calls from primary care physicians to discuss pediatric seizures We hope you enjoy the new season of ParentingU! You can hear all episodes of ParentingU on our website or on your favorite podcast app including Apple Podcasts, Spotify, Stitcher, or Google Podcasts. New! Watch videos of our podcast on YouTube: ParentingU playlist.

Dr. Z Paige Lerario (they/them), vascular neurologist and MSW candidate at Fordham University and transgender activist, and Gabriel Glissmeyer (he/him), Project Specialist at the National LGBT Cancer Network in Salt Lake City, Utah, talk about involving transgender and gender diverse patients in research, and supporting our gender diverse colleagues.

The role of genetics in both pediatric and adult epilepsies is expanding. Now, making a genetic diagnosis in epilepsy isn't just important for family planning and prognostication - these diagnoses can also improve patients' care starting at the moment of diagnosis. Our guest today, Ingrid Scheffer, is a leader in gene discovery in epilepsy. Dr. Scheffer is a Laureate Professor of Pediatric Neurology at the University of Melbourne, and she directs the Children's Epilepsy Research Center at Austin Health. She says while there's still a long way to go before precision medicine is available for the hundreds of known genetic epilepsies, her patients are already benefiting from genetic testing, in many ways. Dr. Scheffer was interviewed by ANA Investigates Producer and epileptologist Dr. Rohit Das of UT Southwestern Medical Center. Series 3, Episode 12. Featuring: Guest: Ingrid Scheffer, AO FRS FAA FAHMS, University of Melbourne Interviewer/Producer: Rohit Das, MD, UT Southwestern Disclosures: In the past 24 months, Ingrid Scheffer has consulted for Atheneum Partners, Biohaven Pharmaceuticals Inc, Care Beyond Diagnosis, Epilepsy Consortium and Zynerba Pharmaceuticals, has served as an investigator for Anavex Life Sciences, Cerebral Therapeutics, Cerecin Inc, Cereval Therapeutics, Eisai, Encoded Therapeutics, EpiMinder Inc, Epygenyx, ES-Therapeutics, GW Pharma, Marinus, Neurocrine BioSciences, Ovid Therapeutics, Takeda Pharmaceuticals, UCB, Ultragenyx, Xenon Pharmaceutical, Zogenix and Zynerba; received speaker honoraria from Biocodex, BioMarin, Chiesi, Liva Nova and UCB; received funding for travel from Biomarin, Eisai and UCB; and served on scientific advisory boards for Bellberry Ltd, BioMarin, Chiesi, Eisai, Encoded Therapeutics, Knopp Biosciences, Rogcon, Takeda Pharmaceuticals and UCB. Ingrid Scheffer may accrue future revenue on pending patent WO2009/086591: Diagnostic And Therapeutic Methods For EFMR (Epilepsy And Mental Retardation Limited To Females); has a patent for SCN1A testing held by Bionomics Inc and licensed to various diagnostic companies (WO/2006/133508); she has a patent for a molecular diagnostic/therapeutic target for benign familial infantile epilepsy (BFIE) [PRRT2] WO/2013/059884 with royalties paid.

This week on Seizing Life ®, Dr. Doug Nordli, Chief of Pediatric Neurology at UChicago Medicine, provides a guide to help parents of children with epilepsy navigate their child's diagnostic and treatment journey. The post A Parent's Guide to Your Child's Epilepsy Diagnosis and Treatment appeared first on CURE Epilepsy.

Dr. Christy talks to Dr. Monica Lemmon, pediatric neurologist and associate professor in pediatrics and population health sciences at Duke Department of Pediatrics, and winner of the 2021 Philip R. Dodge Young Investigator Award from the Child Neurology Society, discusses her work understanding how we communicate with patients and families – and how we can improve that communication.

Dr. Geetanjali Rathore, Associate Professor, Pediatric Neurology, UNMC, Omaha talks with parents of children diagnosed with congenital CMV to hear what they think all parents and healthcare providers should know about CMV. https://www.nationalcmv.org/  

Dr. Hope O'Brien, headache specialist and Associate Editor for headache at JCN, talks about opening her own clinic for headache medicine – The Headache Center of Hope – in Cincinnati, Ohio. https://www.hcohcincy.com/hope-obrien

Mallory Rodgers is not only a Registered Nurse who specializes in Pediatric Neurology but TAYLOR SWIFTS NUMBER ONE FAN BABAYY! We had a wonderful talk about music, life in the emergency lane, and her personal hero; Kanye West. OW OWWW! --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app Support this podcast: https://anchor.fm/beartoes/support

On this week's episode of Talking Pediatrics, Dr. Gabi Hester explores how to diagnose and manage headaches in children with Dr. Meghan Candee, Associate Professor of Pediatric Neurology and Director of the Comprehensive Pediatric Headache Clinic at the University of Utah.View the transcript here:https://www.childrensmn.org/for-health-professionals/talking-pediatrics-podcast/talking-pediatrics-guidelines-gabi-heads-helping-kids-manage-migraines-get-back-play-school-3-18-22/

Dr. Amal Abu Libdeh, pediatric neurologist and movement disorders specialist at the University of Virginia, talks about the challenges that face international medical school graduates, what they bring to the table in pediatric neurology, and how we can help and support them.

The Promise of Discovery Season 2, Episode 7: This episode features a discussion of the need for meaningful therapies in Rett syndrome (RTT), and highlights the Lavender™ study, a phase 3, 12-week, double-blind, randomized, placebo-controlled study of the drug trofinetide in 187 young females, ages 5 to 20, with Rett syndrome. Investigators discuss public, top-level results of the potential first-of-its-kind drug to treat the symptoms of RTT, and share the hope that this trial paves the way for other successful trials in RTT and related disorders. VKC Researchers: Jeffrey L. Neul, M.D., Ph.D., Annette Schaffer Eskind Chair and Director, Vanderbilt Kennedy Center; Professor of Pediatrics, Division of Neurology, Pharmacology, and Special Education Cary Fu, M.D., Assistant Professor of Pediatrics, Pediatric Neurology

Livehealthy editor Ann Marie McQueen interviews Dr Arif Khan, a specialist in pediatric neurology and a consultant and director at Burjeel Medical City in Abu Dhabi. He also founded the first comprehensive children's neuroscience center in the UAE, called Neuropedia. We talk all about what happens before, during and after an autism spectrum disorder diagnosis, the rise of ADHD, and what he sees as the number one problem for all children's brains: screen time.

Dr. Baruch Williams is a licensed psychologist who specializes in neuropsychological assessment of children and young adults. She has obtained extensive training in the cognitive and behavioral development that takes place throughout childhood and young adulthood. Dr. Williams worked as a research assistant at City University of New York Queens College, in the Laboratory of Developmental Neuropsychology and the Laboratory of Biological Psychopathology. She then returned to her hometown of Houston, Texas where she obtained a Clinical Psychology doctoral degree from the University of Houston, with a specialization in neuropsychology (Child Track). She acquired additional training at Texas Children's Hospital Blue Bird Clinic for Pediatric Neurology as well as Memorial Hermann Hospital. After completing an internship at Baylor College of Medicine/Texas Children's Hospital, Dr. Williams completed a post-doctoral residency at Kennedy Krieger Institute, Johns Hopkins School of Medicine. Dr. Williams is experienced in the neuropsychological assessment of children with attention disorders, learning disabilities, behavioral/affective disorders, autism spectrum disorder, epilepsy, prematurity, traumatic brain injury, genetic syndromes, and a host of other medical conditions. --- Send in a voice message: https://podcasters.spotify.com/pod/show/efta/message

In this week's episode, we hear from Dr. Sean Goretzke, who is a Pediatric Neurologist and Division Director of Child Neurology Services at Cardinal Glennon Children's Hospital where he has a special interest in managing children with concussions and cerebral palsy. Dr. Goretzke is also an assistant professor of Pediatric Neurology in the Department of Neurology at Saint Louis University School of Medicine.Dr. Goretzke is the father of six kids and I can say with certainty that this has greatly influenced his very relatable style when practicing medicine, which is something he shares more about in this episode. We touch on a variety of subjects ranging from navigating difficult medication decisions, comfort measures and quality of life discussions, and my personal favorite, the social inequalities that impact healthcare and medicine.VOTE HERE for "Disability" to be a podcast categoryBe sure to visit our Website or Shop for Atypical Truth swag!Music by amiinaCover-art by Kendall BellTranscription provided HEREResearch can be found HERE

At least 3.4+ Million Live with Epilepsy in the U.S.2National Neurology Expert Offers Immediate Steps to Mitigate Deadly Risks, ReduceRelated Healthcare Costs and BurdenGUEST:  Dr. James Wheless, Professor and Chief of Pediatric Neurology, Le Bonheur Chair in Pediatric Neurology, University of Tennessee Health Science CenterBackground:Epilepsy is a disorder of the brain that is characterized by seizures.3 Seizures can be debilitating and even life threatening.4 Just one convulsive seizure is a potentially shattering event that increases the risk of significant health consequences, including physical injury and cognitive decline.5,6,7 Although epilepsy is widely recognized, few understand it – even those who know someone with the disorder.1 And this misunderstanding causes a stigma that makes it harder to treat,1 while the number of adults and children challenged by epilepsy in the U.S. is increasing.2Freedom from seizures is the ultimate goal in epilepsy treatment.8 Yet missed doses are a common occurrence that can get in the way of achieving it. For most people with this condition, it's a question of when, not if they will miss a dose of their medication. In fact, 71% of epilepsy patients surveyed have missed at least 1 dose.9 And, almost 50% report that a missed dose of medication was followed by a subsequent seizure.9 Poor seizure control means a higher likelihood of emergency room visits and greater healthcare costs.10 Yet many with epilepsy may be reluctant to discuss their struggles even with their doctor.11Dr. James Wheless, Professor and Chief of Pediatric Neurology, Le Bonheur Chair in Pediatric Neurology, University of Tennessee Health Science Center will help educate your viewers about epilepsy, including the crucial role of individual lifestyle in treatment, and advances in epilepsy management that will help people living with epilepsy achieve seizure freedom.More information can be found at www.epilapsey.comMore About Dr. James WhelessDr. Wheless is Professor and Chief of Pediatric Neurology and the Le Bonheur Chair in Pediatric Neurology at the University of Tennessee Health Science Center in Memphis. He also serves as Director of the Neuroscience Institute and the Le Bonheur Comprehensive Epilepsy Program for the Le Bonheur Children's Hospital.Dr. Wheless is a paid consultant on behalf of Eisai Inc.REFERENCEHerrmann LK, et al. Epilepsy misconceptions and stigma reduction: Current status in Western Countries. Epilepsy Behav. 2016;60:165-173.Zack MM, Kobau R. National and State Estimates of the Numbers of Adults and Children with Active Epilepsy — the United States, 2015. MMWR Morb Mortal Wkly Rep. 2017;66:821–825.Institute of Medicine Committee on the Public Health Dimensions of the Epilepsies. Summary.  Epilepsy Across the Spectrum: Promoting Health and Understanding. England MJ, Liverman CT, Schultz AM, Strawbridge LM, editors. Washington, DC: National Academies Press; 2012.Harden C, et al. Practice Guideline Summary: Sudden Unexpected Death in Epilepsy Incidence Rates and Risk Factors:  Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsy Currents. 2015;17(3):180-187.Friedman DE, et al. Recurrent seizure-related injuries in people with epilepsy at a tertiary epilepsy center: A 2-year longitudinal study. Epilepsy Behav. 2010;19(3):400-404.Thompson PJ, Duncan JS. Cognitive decline in severe epilepsy. Epilepsia. 2005;45(11):1780-1787.Berg AT, et al. Mortality risks in new-onset childhood epilepsy. Pediatrics. 2013;132(1):124-131St. Louis, EK. Minimizing AED Adverse Effects: Improving Quality of Life in the Interictal State in Epilepsy Care. Current Neuropharmacol. 2009;7:106-114.Cramer JA, Glassman M, Rienzi V. The relationship between poor medication compliance and seizures. Epilepsy Behav. 2002;3:338-342.Divino V, Petrilla AA, Bollu V, et al. Clinical and economic burden of breakthrough seizures. Epilepsy Behav. 2015;51:40-47.Buelow J, Miller W, Fishman J. Development of an Epilepsy Nursing Communication Tool: Improving the Quality of Interactions Between Nurses and Patients with Seizures. Jour of Neurosci Nurs. 2018;50(2):74-80.